Lyell Immunopharma, Inc. (LYEL)

SEC filing

Lyell Immunopharma, Inc.

LYEL · CIK 1806952

4 · Mar 9, 2026 · ARCH Venture Fund IX Overage bought 488.09K shares at $25.61/share ($12.5M)

ARCH Venture Fund IX Overage bought 488.09K shares at $25.61/share ($12.5M)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

xslF345X05/form4.xmlSEC.gov

Graphics and non-inline formats (not embedded below).

4STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIESform4.xml
Open SEC.gov